Announced details
Ophthalmology, pipeline expansion for ophthalmic diseases, discovery of drug target molecules, drug repurposing
Drug Discovery AI Factory has been adopted by multiple major pharmaceutical companies and has an established track record (company names and number of deployments: Not disclosed)
The second co-creation project, following the first project launched in December 2025. FRONTEO will use its AI-powered drug discovery support service and proprietary analytical methods to analyze assets designated by SANTEN PHARMACEUTICAL CO.,LTD.
Head office: Kita-ku, Osaka; Representative Director, President and CEO: Ito Tsuyoshi (伊藤 毅). A global pharmaceutical company specializing in ophthalmology. Founded in Osaka, Japan, in 1890, the company conducts research and development, manufacturing and sales of ophthalmic pharmaceuticals and medical devices. Its products and services are available in more than 60 countries and regions worldwide.
A total of 21 patents have been obtained in Japan, Europe, the United States and South Korea for technologies used in Drug Discovery AI Factory (individual patent numbers and expiration dates: Not disclosed)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
FRONTEO press release dated 18 December 2025 (first co-creation project)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory, KIBIT |
| Counterparty | SANTEN PHARMACEUTICAL CO.,LTD. |
| Counterparty overview | Head office: Kita-ku, Osaka; Representative Director, President and CEO: Ito Tsuyoshi (伊藤 毅). A global pharmaceutical company specializing in ophthalmology. Founded in Osaka, Japan, in 1890, the company conducts research and development, manufacturing and sales of ophthalmic pharmaceuticals and medical devices. Its products and services are available in more than 60 countries and regions worldwide. |
| Relationship with the Company | The second co-creation project, following the first project launched in December 2025. FRONTEO will use its AI-powered drug discovery support service and proprietary analytical methods to analyze assets designated by SANTEN PHARMACEUTICAL CO.,LTD. |
| Launch date | 16 July 2026 (already launched) |
| Applicable area | Ophthalmology, pipeline expansion for ophthalmic diseases, discovery of drug target molecules, drug repurposing |
| Registration number and expiry date | A total of 21 patents have been obtained in Japan, Europe, the United States and South Korea for technologies used in Drug Discovery AI Factory (individual patent numbers and expiration dates: Not disclosed) |
| Usage history | Drug Discovery AI Factory has been adopted by multiple major pharmaceutical companies and has an established track record (company names and number of deployments: Not disclosed) |
| Source | FRONTEO press release dated 18 December 2025 (first co-creation project) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The previous project was highly rated by SANTEN PHARMACEUTICAL CO.,LTD. Through this initiative, the companies aim to expand SANTEN PHARMACEUTICAL CO.,LTD.'s pipeline and address unmet medical needs in ophthalmology.